Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
Copyright © 2023 Hodroj, Abou Dalle, Moukalled, El Cheikh, Mohty and Bazarbachi..
The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with the incorporation of multi-agent chemotherapy in the treatment landscape as well as the recent approval of immunotherapeutic agents allowing a larger proportion of patients to undergo allogeneic hematopoietic cell transplantation (allo-HCT) which is still considered a potential curative approach. However, relapse post-transplant is still occurring and constitutes a common cause of treatment failure in B-ALL. The present review aims to discuss the novel strategies and therapies used to prevent and overcome relapse post allo-HCT in patients with ALL, focusing on the role of tyrosine kinase inhibitors in Philadelphia chromosome positive B-ALL, the role of innovative agents such as blinatumomab and inotuzumab ozogamicin, and finally the role of cellular therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 14(2023) vom: 04., Seite 1191912 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hodroj, Mohammad Hassan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute lymphoblastic leukemia |
|---|
| Anmerkungen: |
Date Completed 28.06.2023 Date Revised 01.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2023.1191912 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35860902X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35860902X | ||
| 003 | DE-627 | ||
| 005 | 20231226210541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2023.1191912 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM35860902X | ||
| 035 | |a (NLM)37359547 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hodroj, Mohammad Hassan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.06.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Hodroj, Abou Dalle, Moukalled, El Cheikh, Mohty and Bazarbachi. | ||
| 520 | |a The outcome of B-cell acute lymphoblastic leukemia (B-ALL) has improved over time with the incorporation of multi-agent chemotherapy in the treatment landscape as well as the recent approval of immunotherapeutic agents allowing a larger proportion of patients to undergo allogeneic hematopoietic cell transplantation (allo-HCT) which is still considered a potential curative approach. However, relapse post-transplant is still occurring and constitutes a common cause of treatment failure in B-ALL. The present review aims to discuss the novel strategies and therapies used to prevent and overcome relapse post allo-HCT in patients with ALL, focusing on the role of tyrosine kinase inhibitors in Philadelphia chromosome positive B-ALL, the role of innovative agents such as blinatumomab and inotuzumab ozogamicin, and finally the role of cellular therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a acute lymphoblastic leukemia | |
| 650 | 4 | |a allogeneic stem cell transplant | |
| 650 | 4 | |a antibody drug conjugates | |
| 650 | 4 | |a bispecific antibodies | |
| 650 | 4 | |a relapse | |
| 650 | 4 | |a tyrosine kinase inhibitors | |
| 650 | 7 | |a Inotuzumab Ozogamicin |2 NLM | |
| 650 | 7 | |a P93RUU11P7 |2 NLM | |
| 700 | 1 | |a Abou Dalle, Iman |e verfasserin |4 aut | |
| 700 | 1 | |a Moukalled, Nour |e verfasserin |4 aut | |
| 700 | 1 | |a El Cheikh, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Mohty, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Bazarbachi, Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 14(2023) vom: 04., Seite 1191912 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g day:04 |g pages:1191912 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2023.1191912 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |b 04 |h 1191912 | ||